Parabilis Medicines, Inc.

Healthcare · Biotechnology · United States

Last price 28.32 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.50B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-ca...